Flannelly Barry P 4
4 · Protara Therapeutics, Inc. · Filed Jun 16, 2026
Research Summary
AI-generated summary of this filing
Protara (TARA) Director Barry P. Flannelly Receives 31,000-Share Award
What Happened
- Barry P. Flannelly, a director of Protara Therapeutics, received a compensatory award of 31,000 shares on 2026-06-15. The shares were granted at $0.00 (derivative award) and have a reported initial value of $0 in the Form 4 filing. This is a director equity grant (not an open-market purchase or sale).
Key Details
- Transaction date: 2026-06-15; filing date: 2026-06-16 (filed the next day).
- Transaction type/code: Award/Grant (A); Price reported $0.00; reported transaction value $0 (derivative).
- Vesting: The shares vest in full on the first anniversary of the grant subject to continuous board service, and will vest in full upon a Change of Control (per filing footnote).
- Shares owned after transaction: Not specified in the filing.
- Timeliness: Filing appears timely (Form 4 filed within required 2 business days).
Context
- This was a compensatory restricted stock award for a director, which is standard executive/director compensation and not the same as an insider buying shares in the open market. Such grants reflect company compensation practices rather than a direct cash investment by the insider.
Insider Transaction Report
Form 4
Flannelly Barry P
Director
Transactions
- Award
Stock Option (Right to Buy)
[F1]2026-06-15+31,000→ 31,000 totalExercise: $3.94From: 2027-06-15Exp: 2036-06-14→ Common Stock (31,000 underlying)
Footnotes (1)
- [F1]1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Signature
/s/ Mary Grendell, Attorney-in-fact|2026-06-16